CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -1.3: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
516.81MUSDvs all stocks (USD)
Revenue (TTM)
89.40MUSDvs all stocks (USD)
Profit Margin
-247.54%vs Biotechnology peers
Beta
1.75xvs all stocks
52-Week Change
6.52%vs all stocks
Market Capitalization
516.81MUSDvs all stocks (USD)
Enterprise Value
-72.26MUSDvs all stocks (USD)
Forward P/E
-2.33xvs Biotechnology peers
Price to Sales (TTM)
5.80xvs Biotechnology peers
Price to Book (MRQ)
1.34xvs Biotechnology peers
Enterprise to Revenue
-0.8080xvs Biotechnology peers
Enterprise to EBITDA
0.2930xvs Biotechnology peers
Profit Margin
-247.54%vs Biotechnology peers
Operating Margin
-405.13%vs Biotechnology peers
Return on Assets (TTM)
-18.92%vs Biotechnology peers
Return on Equity (TTM)
-42.28%vs Biotechnology peers
Revenue (TTM)
89.40MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.30USDUpdated Jul 18, 2026Quarterly Revenue Growth
-91.70%vs Biotechnology peers
EBITDA (TTM)
-246.50MUSDvs all stocks (USD)
Net Income (TTM)
-221.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-91.74%vs Biotechnology peers
Operating Cash Flow (TTM)
-254.10MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-199.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
262.60MUSDFY2025 · Dec 31, 2025Operating Income
-118.50MUSDvs all stocks (USD)
Pre-tax Income
-80.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
300.00KUSDFY2025 · Dec 31, 2025Net Income
-80.80MUSDFY2025 · Dec 31, 2025EBIT
-118.50MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-113.30MUSDFY2025 · Dec 31, 2025Research & Development
285.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
95.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
38.40MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-80.80MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-279.10MUSDFY2025 · Dec 31, 2025Free Cash Flow
-281.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
142.90MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-80.80MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
44.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-8.50MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
7.30MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.70MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-244.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.90MUSDFY2025 · Dec 31, 2025Purchase of Investments
-354.20MUSDFY2025 · Dec 31, 2025Sale of Investments
763.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
407.60MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-200.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-91.90MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-92.10MUSDFY2025 · Dec 31, 2025Shares Outstanding
64.51MSharesUpdated Jul 18, 2026Float Shares
55.80MSharesUpdated Jul 18, 2026Shares Short
4.27MSharesUpdated Jul 18, 2026Short Ratio
4.91daysvs all stocks
Short % of Shares Outstanding
7.73%vs all stocks
% Held by Insiders
7.91%vs all stocks
% Held by Institutions
82.59%vs all stocks
Total Cash (MRQ)
614.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.53USDUpdated Jul 18, 2026Total Debt (MRQ)
8.40MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0217xvs Biotechnology peers
Current Ratio (MRQ)
5.44xvs Biotechnology peers
Book Value per Share (MRQ)
6.00USDUpdated Jul 18, 2026Total Assets
717.90MUSDvs all stocks (USD)
Total Current Assets
700.70MUSDFY2025 · Dec 31, 2025Total Liabilities
284.10MUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.20MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
141.60MUSDFY2025 · Dec 31, 2025Total Current Liabilities
142.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
142.90MUSDFY2025 · Dec 31, 2025Other Short-term Investments
542.50MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.00MUSDFY2025 · Dec 31, 2025Accounts Payable
24.40MUSDFY2025 · Dec 31, 2025Short-term Debt
1.70MUSDFY2025 · Dec 31, 2025Deferred Revenue
71.30MUSDFY2025 · Dec 31, 2025Long-term Debt
7.20MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
100.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-1.61BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
433.80MUSDvs all stocks (USD)
Treasury Stock
91.90MUSDFY2025 · Dec 31, 202552-Week Low
6.06USDUpdated Jul 18, 202652-Week High
14.51USDUpdated Jul 18, 202652-Week Change
6.52%vs all stocks
Beta
1.75xvs all stocks
50-Day MA
8.51USDUpdated Jul 18, 2026200-Day MA
10.71USDUpdated Jul 18, 2026Avg 10-Day Volume
546.11KSharesUpdated Jul 18, 2026Avg 30-Day Volume
760.85KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-3.18USDUpdated Jul 18, 2026Other Income / Expense
-400.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Is this company growing?
Diagnostic
Total Revenue Growth With Buyback Amplification And Heavy SGA
Revenue is growing and buybacks shrink the share count, so per-share growth runs faster.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.44Altman Z-Score: -1.30
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.18Revenue Growth YoY: -0.92
Financial Health
Altman Z-Score -1.3: distress zoneCritical
Altman Z-Score: -1.30
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Cyrela Brazil Realty S.A. Empreendimentos e Participações
1 interpretationHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
SM Entertainment Co., Ltd.
1 interpretationHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Doximity Inc.
1 interpretationTotal Revenue Growth With Buyback Amplification And Heavy SGA